nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—ALOX5—stomach cancer	0.338	0.551	CbGaD
Mesalazine—PPARG—stomach cancer	0.193	0.315	CbGaD
Mesalazine—PTGS2—stomach cancer	0.0817	0.133	CbGaD
Mesalazine—PPARG—Topotecan—Irinotecan—stomach cancer	0.00281	1	CbGdCrCtD
Mesalazine—CHUK—hematopoietic system—stomach cancer	0.00264	0.0435	CbGeAlD
Mesalazine—CHUK—epithelium—stomach cancer	0.00242	0.0397	CbGeAlD
Mesalazine—MPO—blood vessel—stomach cancer	0.00237	0.0389	CbGeAlD
Mesalazine—PPARG—blood vessel—stomach cancer	0.0021	0.0345	CbGeAlD
Mesalazine—CHUK—lymphoid tissue—stomach cancer	0.00186	0.0306	CbGeAlD
Mesalazine—CHUK—digestive system—stomach cancer	0.00184	0.0302	CbGeAlD
Mesalazine—IKBKB—hematopoietic system—stomach cancer	0.0018	0.0295	CbGeAlD
Mesalazine—IKBKB—smooth muscle tissue—stomach cancer	0.00158	0.026	CbGeAlD
Mesalazine—CHUK—endocrine gland—stomach cancer	0.00152	0.025	CbGeAlD
Mesalazine—ALOX5—hematopoietic system—stomach cancer	0.00149	0.0245	CbGeAlD
Mesalazine—CHUK—liver—stomach cancer	0.00137	0.0225	CbGeAlD
Mesalazine—ALOX5—smooth muscle tissue—stomach cancer	0.00131	0.0216	CbGeAlD
Mesalazine—IKBKB—lymphoid tissue—stomach cancer	0.00126	0.0208	CbGeAlD
Mesalazine—MPO—hematopoietic system—stomach cancer	0.00126	0.0207	CbGeAlD
Mesalazine—IKBKB—digestive system—stomach cancer	0.00125	0.0205	CbGeAlD
Mesalazine—ALOX5—pancreas—stomach cancer	0.00121	0.0199	CbGeAlD
Mesalazine—MPO—epithelium—stomach cancer	0.00115	0.0189	CbGeAlD
Mesalazine—PTGS1—blood vessel—stomach cancer	0.00112	0.0185	CbGeAlD
Mesalazine—PPARG—hematopoietic system—stomach cancer	0.00112	0.0184	CbGeAlD
Mesalazine—PTGS2—blood vessel—stomach cancer	0.00107	0.0176	CbGeAlD
Mesalazine—CHUK—lymph node—stomach cancer	0.00105	0.0173	CbGeAlD
Mesalazine—ALOX5—lymphoid tissue—stomach cancer	0.00105	0.0172	CbGeAlD
Mesalazine—ALOX5—digestive system—stomach cancer	0.00104	0.017	CbGeAlD
Mesalazine—IKBKB—endocrine gland—stomach cancer	0.00103	0.017	CbGeAlD
Mesalazine—MPO—pancreas—stomach cancer	0.00103	0.0169	CbGeAlD
Mesalazine—PPARG—epithelium—stomach cancer	0.00102	0.0168	CbGeAlD
Mesalazine—PTGS2—gall bladder—stomach cancer	0.00101	0.0166	CbGeAlD
Mesalazine—PPARG—smooth muscle tissue—stomach cancer	0.000985	0.0162	CbGeAlD
Mesalazine—ALOX5—bone marrow—stomach cancer	0.000954	0.0157	CbGeAlD
Mesalazine—IKBKB—liver—stomach cancer	0.000931	0.0153	CbGeAlD
Mesalazine—PPARG—pancreas—stomach cancer	0.00091	0.015	CbGeAlD
Mesalazine—MPO—lymphoid tissue—stomach cancer	0.000887	0.0146	CbGeAlD
Mesalazine—MPO—digestive system—stomach cancer	0.000876	0.0144	CbGeAlD
Mesalazine—ALOX5—endocrine gland—stomach cancer	0.000856	0.0141	CbGeAlD
Mesalazine—Olsalazine—ALOX5—stomach cancer	0.000842	0.2	CrCbGaD
Mesalazine—MPO—bone marrow—stomach cancer	0.000808	0.0133	CbGeAlD
Mesalazine—Aminosalicylic Acid—ALOX5—stomach cancer	0.000792	0.188	CrCbGaD
Mesalazine—PPARG—lymphoid tissue—stomach cancer	0.000787	0.0129	CbGeAlD
Mesalazine—PPARG—digestive system—stomach cancer	0.000777	0.0128	CbGeAlD
Mesalazine—ALOX5—liver—stomach cancer	0.000771	0.0127	CbGeAlD
Mesalazine—MPO—endocrine gland—stomach cancer	0.000724	0.0119	CbGeAlD
Mesalazine—PPARG—bone marrow—stomach cancer	0.000717	0.0118	CbGeAlD
Mesalazine—IKBKB—lymph node—stomach cancer	0.000714	0.0117	CbGeAlD
Mesalazine—MPO—liver—stomach cancer	0.000653	0.0107	CbGeAlD
Mesalazine—PPARG—endocrine gland—stomach cancer	0.000642	0.0106	CbGeAlD
Mesalazine—PTGS1—hematopoietic system—stomach cancer	0.000598	0.00983	CbGeAlD
Mesalazine—ALOX5—lymph node—stomach cancer	0.000591	0.00972	CbGeAlD
Mesalazine—PPARG—liver—stomach cancer	0.000579	0.00952	CbGeAlD
Mesalazine—PTGS2—hematopoietic system—stomach cancer	0.000571	0.00939	CbGeAlD
Mesalazine—PTGS1—epithelium—stomach cancer	0.000546	0.00898	CbGeAlD
Mesalazine—PTGS1—smooth muscle tissue—stomach cancer	0.000526	0.00866	CbGeAlD
Mesalazine—PTGS2—epithelium—stomach cancer	0.000522	0.00859	CbGeAlD
Mesalazine—PTGS2—smooth muscle tissue—stomach cancer	0.000503	0.00827	CbGeAlD
Mesalazine—MPO—lymph node—stomach cancer	0.0005	0.00823	CbGeAlD
Mesalazine—Olsalazine—PPARG—stomach cancer	0.000482	0.115	CrCbGaD
Mesalazine—PTGS2—pancreas—stomach cancer	0.000465	0.00765	CbGeAlD
Mesalazine—PPARG—lymph node—stomach cancer	0.000444	0.0073	CbGeAlD
Mesalazine—PTGS1—digestive system—stomach cancer	0.000416	0.00683	CbGeAlD
Mesalazine—PTGS2—lymphoid tissue—stomach cancer	0.000402	0.00661	CbGeAlD
Mesalazine—PTGS2—digestive system—stomach cancer	0.000397	0.00653	CbGeAlD
Mesalazine—PTGS2—bone marrow—stomach cancer	0.000366	0.00602	CbGeAlD
Mesalazine—PTGS1—endocrine gland—stomach cancer	0.000343	0.00565	CbGeAlD
Mesalazine—PTGS2—endocrine gland—stomach cancer	0.000328	0.0054	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—stomach cancer	0.000297	0.0706	CrCbGaD
Mesalazine—PTGS2—liver—stomach cancer	0.000296	0.00487	CbGeAlD
Mesalazine—Droxidopa—ADRB1—stomach cancer	0.000251	0.0597	CrCbGaD
Mesalazine—PTGS1—lymph node—stomach cancer	0.000237	0.0039	CbGeAlD
Mesalazine—PTGS2—lymph node—stomach cancer	0.000227	0.00373	CbGeAlD
Mesalazine—Droxidopa—ADRB2—stomach cancer	0.000211	0.0502	CrCbGaD
Mesalazine—Olsalazine—PTGS2—stomach cancer	0.000203	0.0484	CrCbGaD
Mesalazine—Dopamine—ADRB1—stomach cancer	0.000196	0.0467	CrCbGaD
Mesalazine—Diflunisal—PTGS2—stomach cancer	0.000191	0.0455	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—stomach cancer	0.000191	0.0455	CrCbGaD
Mesalazine—Dopamine—HTR1A—stomach cancer	0.000176	0.0418	CrCbGaD
Mesalazine—Diflunisal—ALB—stomach cancer	0.00017	0.0405	CrCbGaD
Mesalazine—Salicylic acid—PTGS2—stomach cancer	0.000106	0.0253	CrCbGaD
Mesalazine—Salicylic acid—ALB—stomach cancer	9.48e-05	0.0225	CrCbGaD
Mesalazine—Musculoskeletal discomfort—Capecitabine—stomach cancer	5.38e-05	0.000308	CcSEcCtD
Mesalazine—Cardiac disorder—Epirubicin—stomach cancer	5.37e-05	0.000308	CcSEcCtD
Mesalazine—Vomiting—Fluorouracil—stomach cancer	5.37e-05	0.000308	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—stomach cancer	5.37e-05	0.000307	CcSEcCtD
Mesalazine—Dyspepsia—Docetaxel—stomach cancer	5.36e-05	0.000307	CcSEcCtD
Mesalazine—Haemorrhage—Doxorubicin—stomach cancer	5.35e-05	0.000307	CcSEcCtD
Mesalazine—Hepatitis—Doxorubicin—stomach cancer	5.35e-05	0.000307	CcSEcCtD
Mesalazine—Insomnia—Capecitabine—stomach cancer	5.34e-05	0.000306	CcSEcCtD
Mesalazine—Rash—Fluorouracil—stomach cancer	5.32e-05	0.000305	CcSEcCtD
Mesalazine—Dermatitis—Fluorouracil—stomach cancer	5.32e-05	0.000305	CcSEcCtD
Mesalazine—Pharyngitis—Doxorubicin—stomach cancer	5.31e-05	0.000304	CcSEcCtD
Mesalazine—Paraesthesia—Capecitabine—stomach cancer	5.3e-05	0.000303	CcSEcCtD
Mesalazine—Decreased appetite—Docetaxel—stomach cancer	5.3e-05	0.000303	CcSEcCtD
Mesalazine—Headache—Fluorouracil—stomach cancer	5.29e-05	0.000303	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—stomach cancer	5.29e-05	0.000303	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—stomach cancer	5.27e-05	0.000302	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—stomach cancer	5.27e-05	0.000302	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Docetaxel—stomach cancer	5.26e-05	0.000301	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—stomach cancer	5.26e-05	0.000301	CcSEcCtD
Mesalazine—Dyspnoea—Capecitabine—stomach cancer	5.26e-05	0.000301	CcSEcCtD
Mesalazine—Fatigue—Docetaxel—stomach cancer	5.25e-05	0.000301	CcSEcCtD
Mesalazine—Angiopathy—Epirubicin—stomach cancer	5.25e-05	0.000301	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—stomach cancer	5.25e-05	0.000301	CcSEcCtD
Mesalazine—Nausea—Irinotecan—stomach cancer	5.24e-05	0.0003	CcSEcCtD
Mesalazine—Immune system disorder—Epirubicin—stomach cancer	5.23e-05	0.000299	CcSEcCtD
Mesalazine—Mediastinal disorder—Epirubicin—stomach cancer	5.21e-05	0.000299	CcSEcCtD
Mesalazine—Constipation—Docetaxel—stomach cancer	5.21e-05	0.000299	CcSEcCtD
Mesalazine—Pain—Docetaxel—stomach cancer	5.21e-05	0.000299	CcSEcCtD
Mesalazine—Back pain—Methotrexate—stomach cancer	5.21e-05	0.000298	CcSEcCtD
Mesalazine—Dyspepsia—Capecitabine—stomach cancer	5.19e-05	0.000298	CcSEcCtD
Mesalazine—Chills—Epirubicin—stomach cancer	5.19e-05	0.000297	CcSEcCtD
Mesalazine—Decreased appetite—Capecitabine—stomach cancer	5.13e-05	0.000294	CcSEcCtD
Mesalazine—Alopecia—Epirubicin—stomach cancer	5.11e-05	0.000293	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Capecitabine—stomach cancer	5.09e-05	0.000292	CcSEcCtD
Mesalazine—Fatigue—Capecitabine—stomach cancer	5.09e-05	0.000291	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—stomach cancer	5.07e-05	0.000291	CcSEcCtD
Mesalazine—Mental disorder—Epirubicin—stomach cancer	5.07e-05	0.00029	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—stomach cancer	5.06e-05	0.00029	CcSEcCtD
Mesalazine—Pain—Capecitabine—stomach cancer	5.05e-05	0.000289	CcSEcCtD
Mesalazine—Constipation—Capecitabine—stomach cancer	5.05e-05	0.000289	CcSEcCtD
Mesalazine—Erythema—Epirubicin—stomach cancer	5.04e-05	0.000289	CcSEcCtD
Mesalazine—Feeling abnormal—Docetaxel—stomach cancer	5.02e-05	0.000288	CcSEcCtD
Mesalazine—Nausea—Fluorouracil—stomach cancer	5.02e-05	0.000287	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—stomach cancer	5e-05	0.000287	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—stomach cancer	4.99e-05	0.000286	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—stomach cancer	4.99e-05	0.000286	CcSEcCtD
Mesalazine—Gastrointestinal pain—Docetaxel—stomach cancer	4.98e-05	0.000285	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—stomach cancer	4.97e-05	0.000285	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—stomach cancer	4.97e-05	0.000285	CcSEcCtD
Mesalazine—Flatulence—Epirubicin—stomach cancer	4.96e-05	0.000284	CcSEcCtD
Mesalazine—Tension—Epirubicin—stomach cancer	4.94e-05	0.000283	CcSEcCtD
Mesalazine—Dysgeusia—Epirubicin—stomach cancer	4.93e-05	0.000283	CcSEcCtD
Mesalazine—Nervousness—Epirubicin—stomach cancer	4.89e-05	0.00028	CcSEcCtD
Mesalazine—Back pain—Epirubicin—stomach cancer	4.87e-05	0.000279	CcSEcCtD
Mesalazine—Feeling abnormal—Capecitabine—stomach cancer	4.86e-05	0.000279	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—stomach cancer	4.86e-05	0.000278	CcSEcCtD
Mesalazine—Malaise—Methotrexate—stomach cancer	4.85e-05	0.000278	CcSEcCtD
Mesalazine—Muscle spasms—Epirubicin—stomach cancer	4.84e-05	0.000277	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—stomach cancer	4.84e-05	0.000277	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—stomach cancer	4.84e-05	0.000277	CcSEcCtD
Mesalazine—Gastrointestinal pain—Capecitabine—stomach cancer	4.82e-05	0.000276	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—stomach cancer	4.82e-05	0.000276	CcSEcCtD
Mesalazine—Body temperature increased—Docetaxel—stomach cancer	4.82e-05	0.000276	CcSEcCtD
Mesalazine—Abdominal pain—Docetaxel—stomach cancer	4.82e-05	0.000276	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—stomach cancer	4.82e-05	0.000276	CcSEcCtD
Mesalazine—Chills—Doxorubicin—stomach cancer	4.8e-05	0.000275	CcSEcCtD
Mesalazine—Vision blurred—Epirubicin—stomach cancer	4.75e-05	0.000272	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—stomach cancer	4.73e-05	0.000271	CcSEcCtD
Mesalazine—Cough—Methotrexate—stomach cancer	4.7e-05	0.000269	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—stomach cancer	4.69e-05	0.000269	CcSEcCtD
Mesalazine—Urticaria—Capecitabine—stomach cancer	4.69e-05	0.000268	CcSEcCtD
Mesalazine—Ill-defined disorder—Epirubicin—stomach cancer	4.67e-05	0.000268	CcSEcCtD
Mesalazine—Body temperature increased—Capecitabine—stomach cancer	4.66e-05	0.000267	CcSEcCtD
Mesalazine—Abdominal pain—Capecitabine—stomach cancer	4.66e-05	0.000267	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—stomach cancer	4.66e-05	0.000267	CcSEcCtD
Mesalazine—Anaemia—Epirubicin—stomach cancer	4.65e-05	0.000267	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—stomach cancer	4.59e-05	0.000263	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—stomach cancer	4.58e-05	0.000262	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—stomach cancer	4.58e-05	0.000262	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—stomach cancer	4.58e-05	0.000262	CcSEcCtD
Mesalazine—Tension—Doxorubicin—stomach cancer	4.57e-05	0.000262	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—stomach cancer	4.56e-05	0.000261	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	4.55e-05	0.000261	CcSEcCtD
Mesalazine—Malaise—Epirubicin—stomach cancer	4.54e-05	0.00026	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—stomach cancer	4.53e-05	0.000259	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—stomach cancer	4.53e-05	0.000259	CcSEcCtD
Mesalazine—Vertigo—Epirubicin—stomach cancer	4.52e-05	0.000259	CcSEcCtD
Mesalazine—Syncope—Epirubicin—stomach cancer	4.52e-05	0.000259	CcSEcCtD
Mesalazine—Leukopenia—Epirubicin—stomach cancer	4.51e-05	0.000258	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—stomach cancer	4.51e-05	0.000258	CcSEcCtD
Mesalazine—Hypersensitivity—Docetaxel—stomach cancer	4.49e-05	0.000257	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—stomach cancer	4.48e-05	0.000257	CcSEcCtD
Mesalazine—Palpitations—Epirubicin—stomach cancer	4.45e-05	0.000255	CcSEcCtD
Mesalazine—Confusional state—Methotrexate—stomach cancer	4.43e-05	0.000254	CcSEcCtD
Mesalazine—Loss of consciousness—Epirubicin—stomach cancer	4.43e-05	0.000254	CcSEcCtD
Mesalazine—Cough—Epirubicin—stomach cancer	4.39e-05	0.000252	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—stomach cancer	4.39e-05	0.000252	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—stomach cancer	4.39e-05	0.000252	CcSEcCtD
Mesalazine—Asthenia—Docetaxel—stomach cancer	4.37e-05	0.00025	CcSEcCtD
Mesalazine—Infection—Methotrexate—stomach cancer	4.36e-05	0.00025	CcSEcCtD
Mesalazine—Hypertension—Epirubicin—stomach cancer	4.35e-05	0.000249	CcSEcCtD
Mesalazine—Hypersensitivity—Capecitabine—stomach cancer	4.35e-05	0.000249	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—stomach cancer	4.32e-05	0.000248	CcSEcCtD
Mesalazine—Pruritus—Docetaxel—stomach cancer	4.31e-05	0.000247	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—stomach cancer	4.31e-05	0.000247	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—stomach cancer	4.31e-05	0.000247	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—stomach cancer	4.3e-05	0.000246	CcSEcCtD
Mesalazine—Chest pain—Epirubicin—stomach cancer	4.29e-05	0.000246	CcSEcCtD
Mesalazine—Arthralgia—Epirubicin—stomach cancer	4.29e-05	0.000246	CcSEcCtD
Mesalazine—Myalgia—Epirubicin—stomach cancer	4.29e-05	0.000246	CcSEcCtD
Mesalazine—Anxiety—Epirubicin—stomach cancer	4.27e-05	0.000245	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—stomach cancer	4.27e-05	0.000244	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	4.26e-05	0.000244	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—stomach cancer	4.25e-05	0.000243	CcSEcCtD
Mesalazine—Discomfort—Epirubicin—stomach cancer	4.24e-05	0.000243	CcSEcCtD
Mesalazine—Asthenia—Capecitabine—stomach cancer	4.23e-05	0.000242	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—stomach cancer	4.2e-05	0.000241	CcSEcCtD
Mesalazine—Dry mouth—Epirubicin—stomach cancer	4.19e-05	0.00024	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—stomach cancer	4.19e-05	0.00024	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—stomach cancer	4.19e-05	0.00024	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—stomach cancer	4.18e-05	0.000239	CcSEcCtD
Mesalazine—Pruritus—Capecitabine—stomach cancer	4.17e-05	0.000239	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—stomach cancer	4.17e-05	0.000239	CcSEcCtD
Mesalazine—Diarrhoea—Docetaxel—stomach cancer	4.17e-05	0.000239	CcSEcCtD
Mesalazine—Confusional state—Epirubicin—stomach cancer	4.14e-05	0.000237	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—stomach cancer	4.12e-05	0.000236	CcSEcCtD
Mesalazine—Oedema—Epirubicin—stomach cancer	4.11e-05	0.000235	CcSEcCtD
Mesalazine—Anaphylactic shock—Epirubicin—stomach cancer	4.11e-05	0.000235	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—stomach cancer	4.1e-05	0.000235	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—stomach cancer	4.1e-05	0.000235	CcSEcCtD
Mesalazine—Infection—Epirubicin—stomach cancer	4.08e-05	0.000234	CcSEcCtD
Mesalazine—Cough—Doxorubicin—stomach cancer	4.07e-05	0.000233	CcSEcCtD
Mesalazine—Shock—Epirubicin—stomach cancer	4.04e-05	0.000232	CcSEcCtD
Mesalazine—Diarrhoea—Capecitabine—stomach cancer	4.04e-05	0.000231	CcSEcCtD
Mesalazine—Nervous system disorder—Epirubicin—stomach cancer	4.03e-05	0.000231	CcSEcCtD
Mesalazine—Dizziness—Docetaxel—stomach cancer	4.03e-05	0.000231	CcSEcCtD
Mesalazine—Thrombocytopenia—Epirubicin—stomach cancer	4.02e-05	0.000231	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—stomach cancer	4.02e-05	0.00023	CcSEcCtD
Mesalazine—Tachycardia—Epirubicin—stomach cancer	4.01e-05	0.00023	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methotrexate—stomach cancer	4e-05	0.000229	CcSEcCtD
Mesalazine—Skin disorder—Epirubicin—stomach cancer	3.99e-05	0.000229	CcSEcCtD
Mesalazine—Hyperhidrosis—Epirubicin—stomach cancer	3.97e-05	0.000228	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—stomach cancer	3.97e-05	0.000228	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—stomach cancer	3.97e-05	0.000227	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—stomach cancer	3.97e-05	0.000227	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—stomach cancer	3.97e-05	0.000227	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—stomach cancer	3.95e-05	0.000226	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—stomach cancer	3.94e-05	0.000226	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	3.94e-05	0.000226	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—stomach cancer	3.92e-05	0.000225	CcSEcCtD
Mesalazine—Anorexia—Epirubicin—stomach cancer	3.92e-05	0.000224	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—stomach cancer	3.92e-05	0.000224	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—stomach cancer	3.9e-05	0.000224	CcSEcCtD
Mesalazine—Dizziness—Capecitabine—stomach cancer	3.9e-05	0.000223	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—stomach cancer	3.88e-05	0.000222	CcSEcCtD
Mesalazine—Vomiting—Docetaxel—stomach cancer	3.87e-05	0.000222	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—stomach cancer	3.87e-05	0.000221	CcSEcCtD
Mesalazine—Rash—Docetaxel—stomach cancer	3.84e-05	0.00022	CcSEcCtD
Mesalazine—Hypotension—Epirubicin—stomach cancer	3.84e-05	0.00022	CcSEcCtD
Mesalazine—Dermatitis—Docetaxel—stomach cancer	3.84e-05	0.00022	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—stomach cancer	3.83e-05	0.00022	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—stomach cancer	3.82e-05	0.000219	CcSEcCtD
Mesalazine—Headache—Docetaxel—stomach cancer	3.82e-05	0.000219	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—stomach cancer	3.8e-05	0.000218	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—stomach cancer	3.8e-05	0.000218	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—stomach cancer	3.79e-05	0.000217	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—stomach cancer	3.79e-05	0.000217	CcSEcCtD
Mesalazine—Infection—Doxorubicin—stomach cancer	3.78e-05	0.000216	CcSEcCtD
Mesalazine—Pain—Methotrexate—stomach cancer	3.76e-05	0.000215	CcSEcCtD
Mesalazine—Vomiting—Capecitabine—stomach cancer	3.75e-05	0.000215	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Epirubicin—stomach cancer	3.74e-05	0.000215	CcSEcCtD
Mesalazine—Shock—Doxorubicin—stomach cancer	3.74e-05	0.000214	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—stomach cancer	3.73e-05	0.000214	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—stomach cancer	3.72e-05	0.000213	CcSEcCtD
Mesalazine—Rash—Capecitabine—stomach cancer	3.72e-05	0.000213	CcSEcCtD
Mesalazine—Insomnia—Epirubicin—stomach cancer	3.72e-05	0.000213	CcSEcCtD
Mesalazine—Dermatitis—Capecitabine—stomach cancer	3.72e-05	0.000213	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—stomach cancer	3.71e-05	0.000213	CcSEcCtD
Mesalazine—Headache—Capecitabine—stomach cancer	3.7e-05	0.000212	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—stomach cancer	3.69e-05	0.000212	CcSEcCtD
Mesalazine—Paraesthesia—Epirubicin—stomach cancer	3.69e-05	0.000211	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—stomach cancer	3.68e-05	0.000211	CcSEcCtD
Mesalazine—Dyspnoea—Epirubicin—stomach cancer	3.66e-05	0.00021	CcSEcCtD
Mesalazine—Somnolence—Epirubicin—stomach cancer	3.65e-05	0.000209	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—stomach cancer	3.63e-05	0.000208	CcSEcCtD
Mesalazine—Nausea—Docetaxel—stomach cancer	3.62e-05	0.000207	CcSEcCtD
Mesalazine—Feeling abnormal—Methotrexate—stomach cancer	3.62e-05	0.000207	CcSEcCtD
Mesalazine—Dyspepsia—Epirubicin—stomach cancer	3.62e-05	0.000207	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—stomach cancer	3.59e-05	0.000206	CcSEcCtD
Mesalazine—Decreased appetite—Epirubicin—stomach cancer	3.57e-05	0.000205	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—stomach cancer	3.55e-05	0.000204	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Epirubicin—stomach cancer	3.55e-05	0.000203	CcSEcCtD
Mesalazine—Fatigue—Epirubicin—stomach cancer	3.54e-05	0.000203	CcSEcCtD
Mesalazine—Constipation—Epirubicin—stomach cancer	3.51e-05	0.000201	CcSEcCtD
Mesalazine—Pain—Epirubicin—stomach cancer	3.51e-05	0.000201	CcSEcCtD
Mesalazine—Nausea—Capecitabine—stomach cancer	3.5e-05	0.000201	CcSEcCtD
Mesalazine—Urticaria—Methotrexate—stomach cancer	3.49e-05	0.0002	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—stomach cancer	3.47e-05	0.000199	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—stomach cancer	3.47e-05	0.000199	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—stomach cancer	3.46e-05	0.000198	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—stomach cancer	3.44e-05	0.000197	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—stomach cancer	3.42e-05	0.000196	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—stomach cancer	3.39e-05	0.000194	CcSEcCtD
Mesalazine—Feeling abnormal—Epirubicin—stomach cancer	3.39e-05	0.000194	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—stomach cancer	3.38e-05	0.000194	CcSEcCtD
Mesalazine—Gastrointestinal pain—Epirubicin—stomach cancer	3.36e-05	0.000193	CcSEcCtD
Mesalazine—Dyspepsia—Doxorubicin—stomach cancer	3.35e-05	0.000192	CcSEcCtD
Mesalazine—Decreased appetite—Doxorubicin—stomach cancer	3.31e-05	0.000189	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Doxorubicin—stomach cancer	3.28e-05	0.000188	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—stomach cancer	3.28e-05	0.000188	CcSEcCtD
Mesalazine—Urticaria—Epirubicin—stomach cancer	3.27e-05	0.000187	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—stomach cancer	3.25e-05	0.000186	CcSEcCtD
Mesalazine—Pain—Doxorubicin—stomach cancer	3.25e-05	0.000186	CcSEcCtD
Mesalazine—Abdominal pain—Epirubicin—stomach cancer	3.25e-05	0.000186	CcSEcCtD
Mesalazine—Body temperature increased—Epirubicin—stomach cancer	3.25e-05	0.000186	CcSEcCtD
Mesalazine—Hypersensitivity—Methotrexate—stomach cancer	3.24e-05	0.000185	CcSEcCtD
Mesalazine—Asthenia—Methotrexate—stomach cancer	3.15e-05	0.000181	CcSEcCtD
Mesalazine—Feeling abnormal—Doxorubicin—stomach cancer	3.13e-05	0.00018	CcSEcCtD
Mesalazine—Gastrointestinal pain—Doxorubicin—stomach cancer	3.11e-05	0.000178	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—stomach cancer	3.11e-05	0.000178	CcSEcCtD
Mesalazine—Hypersensitivity—Epirubicin—stomach cancer	3.03e-05	0.000173	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—stomach cancer	3.02e-05	0.000173	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—stomach cancer	3.01e-05	0.000172	CcSEcCtD
Mesalazine—Body temperature increased—Doxorubicin—stomach cancer	3.01e-05	0.000172	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—stomach cancer	3.01e-05	0.000172	CcSEcCtD
Mesalazine—Asthenia—Epirubicin—stomach cancer	2.95e-05	0.000169	CcSEcCtD
Mesalazine—Pruritus—Epirubicin—stomach cancer	2.91e-05	0.000167	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—stomach cancer	2.9e-05	0.000166	CcSEcCtD
Mesalazine—Diarrhoea—Epirubicin—stomach cancer	2.81e-05	0.000161	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—stomach cancer	2.8e-05	0.000161	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—stomach cancer	2.79e-05	0.00016	CcSEcCtD
Mesalazine—Rash—Methotrexate—stomach cancer	2.77e-05	0.000159	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—stomach cancer	2.77e-05	0.000158	CcSEcCtD
Mesalazine—Headache—Methotrexate—stomach cancer	2.75e-05	0.000158	CcSEcCtD
Mesalazine—Asthenia—Doxorubicin—stomach cancer	2.73e-05	0.000156	CcSEcCtD
Mesalazine—Dizziness—Epirubicin—stomach cancer	2.72e-05	0.000156	CcSEcCtD
Mesalazine—Pruritus—Doxorubicin—stomach cancer	2.69e-05	0.000154	CcSEcCtD
Mesalazine—Vomiting—Epirubicin—stomach cancer	2.61e-05	0.00015	CcSEcCtD
Mesalazine—Nausea—Methotrexate—stomach cancer	2.61e-05	0.000149	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—stomach cancer	2.6e-05	0.000149	CcSEcCtD
Mesalazine—Rash—Epirubicin—stomach cancer	2.59e-05	0.000148	CcSEcCtD
Mesalazine—Dermatitis—Epirubicin—stomach cancer	2.59e-05	0.000148	CcSEcCtD
Mesalazine—Headache—Epirubicin—stomach cancer	2.57e-05	0.000148	CcSEcCtD
Mesalazine—Dizziness—Doxorubicin—stomach cancer	2.51e-05	0.000144	CcSEcCtD
Mesalazine—Nausea—Epirubicin—stomach cancer	2.44e-05	0.00014	CcSEcCtD
Mesalazine—Vomiting—Doxorubicin—stomach cancer	2.42e-05	0.000139	CcSEcCtD
Mesalazine—Rash—Doxorubicin—stomach cancer	2.4e-05	0.000137	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—stomach cancer	2.4e-05	0.000137	CcSEcCtD
Mesalazine—Headache—Doxorubicin—stomach cancer	2.38e-05	0.000136	CcSEcCtD
Mesalazine—Nausea—Doxorubicin—stomach cancer	2.26e-05	0.000129	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—ADRB1—stomach cancer	9.23e-06	6.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTHFR—stomach cancer	9.2e-06	6.38e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—DPYD—stomach cancer	9.17e-06	6.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CDKN1A—stomach cancer	9.16e-06	6.35e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ENO1—stomach cancer	9.07e-06	6.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDKN1B—stomach cancer	9e-06	6.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HBEGF—stomach cancer	8.94e-06	6.2e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—JUN—stomach cancer	8.92e-06	6.18e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TNF—stomach cancer	8.88e-06	6.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RPS6—stomach cancer	8.82e-06	6.12e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—KRAS—stomach cancer	8.81e-06	6.11e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IRS2—stomach cancer	8.75e-06	6.07e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PRKCB—stomach cancer	8.75e-06	6.06e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ERCC2—stomach cancer	8.73e-06	6.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6ST—stomach cancer	8.71e-06	6.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CDKN1A—stomach cancer	8.65e-06	6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IRS2—stomach cancer	8.59e-06	5.96e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CD44—stomach cancer	8.49e-06	5.88e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CAV1—stomach cancer	8.48e-06	5.88e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—APOA1—stomach cancer	8.46e-06	5.87e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—stomach cancer	8.46e-06	5.86e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK8—stomach cancer	8.44e-06	5.85e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	8.31e-06	5.76e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDKN1A—stomach cancer	8.3e-06	5.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ADRB2—stomach cancer	8.25e-06	5.72e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	8.23e-06	5.71e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RPS6—stomach cancer	8.23e-06	5.71e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—MTHFR—stomach cancer	8.21e-06	5.69e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MAPK3—stomach cancer	8.13e-06	5.64e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HBEGF—stomach cancer	8.11e-06	5.62e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTT1—stomach cancer	8.11e-06	5.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PPP2R1A—stomach cancer	8.09e-06	5.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD44—stomach cancer	8.04e-06	5.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6ST—stomach cancer	8.04e-06	5.58e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP2A6—stomach cancer	8.01e-06	5.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PRKCB—stomach cancer	7.93e-06	5.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6ST—stomach cancer	7.9e-06	5.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CASP8—stomach cancer	7.8e-06	5.41e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKR1C3—stomach cancer	7.79e-06	5.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6R—stomach cancer	7.77e-06	5.39e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MAPK1—stomach cancer	7.74e-06	5.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—stomach cancer	7.73e-06	5.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—APC—stomach cancer	7.73e-06	5.36e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—SERPINE1—stomach cancer	7.71e-06	5.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDH1—stomach cancer	7.7e-06	5.34e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ENO1—stomach cancer	7.6e-06	5.27e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CAV1—stomach cancer	7.57e-06	5.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HBEGF—stomach cancer	7.56e-06	5.24e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—APOA1—stomach cancer	7.55e-06	5.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SMAD4—stomach cancer	7.51e-06	5.21e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—HRAS—stomach cancer	7.49e-06	5.19e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ADRB2—stomach cancer	7.48e-06	5.19e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—ALB—stomach cancer	7.47e-06	5.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—stomach cancer	7.43e-06	5.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK3—stomach cancer	7.37e-06	5.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PPP2R1A—stomach cancer	7.33e-06	5.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KRAS—stomach cancer	7.31e-06	5.07e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	7.23e-06	5.01e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPP2R1A—stomach cancer	7.22e-06	5e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6R—stomach cancer	7.18e-06	4.98e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—IL6—stomach cancer	7.17e-06	4.97e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FYN—stomach cancer	7.13e-06	4.94e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTP1—stomach cancer	7.08e-06	4.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CASP8—stomach cancer	7.07e-06	4.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6R—stomach cancer	7.05e-06	4.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KRAS—stomach cancer	7.02e-06	4.86e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK1—stomach cancer	7.01e-06	4.86e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—stomach cancer	7.01e-06	4.86e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDH1—stomach cancer	6.98e-06	4.84e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HMOX1—stomach cancer	6.98e-06	4.84e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PPP2R1A—stomach cancer	6.84e-06	4.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SMAD4—stomach cancer	6.81e-06	4.72e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CD44—stomach cancer	6.74e-06	4.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—stomach cancer	6.73e-06	4.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—SERPINE1—stomach cancer	6.72e-06	4.66e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PIK3CA—stomach cancer	6.71e-06	4.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGFR2—stomach cancer	6.69e-06	4.64e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KRAS—stomach cancer	6.63e-06	4.59e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TYMS—stomach cancer	6.58e-06	4.56e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTM1—stomach cancer	6.5e-06	4.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERBB2—stomach cancer	6.5e-06	4.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—RHOA—stomach cancer	6.48e-06	4.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FYN—stomach cancer	6.46e-06	4.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—stomach cancer	6.45e-06	4.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOS3—stomach cancer	6.42e-06	4.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—stomach cancer	6.36e-06	4.41e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SMAD4—stomach cancer	6.35e-06	4.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—stomach cancer	6.21e-06	4.31e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IRS2—stomach cancer	6.13e-06	4.25e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ERCC2—stomach cancer	6.11e-06	4.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—stomach cancer	6.09e-06	4.22e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGFR2—stomach cancer	6.07e-06	4.21e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FYN—stomach cancer	6.03e-06	4.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1B—stomach cancer	6.02e-06	4.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERBB2—stomach cancer	6e-06	4.16e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ALB—stomach cancer	5.98e-06	4.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—stomach cancer	5.96e-06	4.13e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—stomach cancer	5.94e-06	4.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CAV1—stomach cancer	5.94e-06	4.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOA1—stomach cancer	5.93e-06	4.11e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL1B—stomach cancer	5.91e-06	4.1e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB2—stomach cancer	5.89e-06	4.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—stomach cancer	5.87e-06	4.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—stomach cancer	5.85e-06	4.05e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERCC2—stomach cancer	5.8e-06	4.02e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MTHFR—stomach cancer	5.75e-06	3.99e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—JUN—stomach cancer	5.73e-06	3.97e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPP2R1A—stomach cancer	5.73e-06	3.97e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—NOS3—stomach cancer	5.72e-06	3.97e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGFR2—stomach cancer	5.66e-06	3.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PRKCB—stomach cancer	5.65e-06	3.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6ST—stomach cancer	5.63e-06	3.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—stomach cancer	5.63e-06	3.9e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTP1—stomach cancer	5.62e-06	3.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1B—stomach cancer	5.56e-06	3.85e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IRS2—stomach cancer	5.56e-06	3.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1A—stomach cancer	5.55e-06	3.85e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HMOX1—stomach cancer	5.54e-06	3.84e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1B—stomach cancer	5.46e-06	3.78e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTHFR—stomach cancer	5.45e-06	3.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK8—stomach cancer	5.42e-06	3.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APC—stomach cancer	5.41e-06	3.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—stomach cancer	5.41e-06	3.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—stomach cancer	5.39e-06	3.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CAV1—stomach cancer	5.39e-06	3.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOA1—stomach cancer	5.37e-06	3.73e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1B—stomach cancer	5.36e-06	3.72e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CAV1—stomach cancer	5.3e-06	3.68e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOA1—stomach cancer	5.29e-06	3.67e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—stomach cancer	5.23e-06	3.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TYMS—stomach cancer	5.22e-06	3.62e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—stomach cancer	5.2e-06	3.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—JUN—stomach cancer	5.2e-06	3.6e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IRS2—stomach cancer	5.18e-06	3.59e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTM1—stomach cancer	5.16e-06	3.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1A—stomach cancer	5.13e-06	3.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PRKCB—stomach cancer	5.13e-06	3.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6ST—stomach cancer	5.11e-06	3.54e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	5.07e-06	3.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1A—stomach cancer	5.04e-06	3.49e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CAV1—stomach cancer	5.03e-06	3.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6R—stomach cancer	5.03e-06	3.48e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MAPK3—stomach cancer	5.02e-06	3.48e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOA1—stomach cancer	5.01e-06	3.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—stomach cancer	4.96e-06	3.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK8—stomach cancer	4.92e-06	3.41e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APC—stomach cancer	4.91e-06	3.4e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—stomach cancer	4.88e-06	3.38e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ERCC2—stomach cancer	4.85e-06	3.37e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6ST—stomach cancer	4.76e-06	3.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK3—stomach cancer	4.74e-06	3.28e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SERPINE1—stomach cancer	4.71e-06	3.26e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—stomach cancer	4.66e-06	3.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APC—stomach cancer	4.58e-06	3.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—stomach cancer	4.58e-06	3.17e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MTHFR—stomach cancer	4.56e-06	3.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6R—stomach cancer	4.56e-06	3.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RHOA—stomach cancer	4.54e-06	3.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK1—stomach cancer	4.51e-06	3.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—stomach cancer	4.5e-06	3.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—stomach cancer	4.49e-06	3.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOS3—stomach cancer	4.49e-06	3.11e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK3—stomach cancer	4.37e-06	3.03e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK3—stomach cancer	4.29e-06	2.98e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SERPINE1—stomach cancer	4.27e-06	2.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—stomach cancer	4.26e-06	2.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—stomach cancer	4.25e-06	2.95e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6R—stomach cancer	4.25e-06	2.95e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CAV1—stomach cancer	4.21e-06	2.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB2—stomach cancer	4.2e-06	2.91e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOA1—stomach cancer	4.2e-06	2.91e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALB—stomach cancer	4.19e-06	2.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK1—stomach cancer	4.16e-06	2.88e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—stomach cancer	4.16e-06	2.88e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RHOA—stomach cancer	4.12e-06	2.85e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK1—stomach cancer	4.09e-06	2.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—stomach cancer	4.08e-06	2.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOS3—stomach cancer	4.07e-06	2.82e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	4.02e-06	2.79e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NOS3—stomach cancer	4.01e-06	2.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL8—stomach cancer	3.98e-06	2.76e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SERPINE1—stomach cancer	3.98e-06	2.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—stomach cancer	3.93e-06	2.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—stomach cancer	3.91e-06	2.71e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1B—stomach cancer	3.89e-06	2.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—stomach cancer	3.86e-06	2.68e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RHOA—stomach cancer	3.84e-06	2.66e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB2—stomach cancer	3.81e-06	2.64e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS3—stomach cancer	3.8e-06	2.63e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—stomach cancer	3.71e-06	2.57e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—JUN—stomach cancer	3.7e-06	2.57e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—stomach cancer	3.7e-06	2.57e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—stomach cancer	3.67e-06	2.54e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—stomach cancer	3.62e-06	2.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL8—stomach cancer	3.61e-06	2.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—stomach cancer	3.61e-06	2.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—stomach cancer	3.6e-06	2.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1A—stomach cancer	3.59e-06	2.49e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB2—stomach cancer	3.55e-06	2.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—stomach cancer	3.55e-06	2.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1B—stomach cancer	3.53e-06	2.45e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK8—stomach cancer	3.51e-06	2.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—stomach cancer	3.46e-06	2.4e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—stomach cancer	3.37e-06	2.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JUN—stomach cancer	3.36e-06	2.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—stomach cancer	3.34e-06	2.32e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALB—stomach cancer	3.33e-06	2.31e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1B—stomach cancer	3.29e-06	2.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—stomach cancer	3.28e-06	2.27e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—stomach cancer	3.27e-06	2.27e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1A—stomach cancer	3.26e-06	2.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—stomach cancer	3.24e-06	2.24e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—stomach cancer	3.22e-06	2.23e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—stomach cancer	3.2e-06	2.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—stomach cancer	3.2e-06	2.22e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NOS3—stomach cancer	3.18e-06	2.21e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK8—stomach cancer	3.18e-06	2.2e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—stomach cancer	3.14e-06	2.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK3—stomach cancer	3.06e-06	2.12e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1A—stomach cancer	3.04e-06	2.11e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—stomach cancer	2.98e-06	2.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—stomach cancer	2.93e-06	2.03e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK1—stomach cancer	2.91e-06	2.02e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—stomach cancer	2.91e-06	2.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—stomach cancer	2.91e-06	2.01e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK3—stomach cancer	2.78e-06	1.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—stomach cancer	2.75e-06	1.91e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—stomach cancer	2.71e-06	1.88e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—stomach cancer	2.7e-06	1.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK1—stomach cancer	2.64e-06	1.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—stomach cancer	2.64e-06	1.83e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK3—stomach cancer	2.59e-06	1.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—stomach cancer	2.53e-06	1.75e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—stomach cancer	2.52e-06	1.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—stomach cancer	2.49e-06	1.73e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK1—stomach cancer	2.46e-06	1.71e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—stomach cancer	2.46e-06	1.71e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—stomach cancer	2.45e-06	1.7e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—stomach cancer	2.34e-06	1.62e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—stomach cancer	2.33e-06	1.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—stomach cancer	2.29e-06	1.59e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—stomach cancer	2.26e-06	1.56e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—stomach cancer	2.24e-06	1.55e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—stomach cancer	2.22e-06	1.54e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—stomach cancer	2.14e-06	1.48e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—stomach cancer	2.12e-06	1.47e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—stomach cancer	2.03e-06	1.41e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—stomach cancer	1.98e-06	1.37e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—stomach cancer	1.89e-06	1.31e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—stomach cancer	1.79e-06	1.24e-05	CbGpPWpGaD
